Premium
What are the nursing implications when using paliperidone prolonged release for people with schizophrenia
Author(s) -
JONES A.
Publication year - 2008
Publication title -
journal of psychiatric and mental health nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 63
eISSN - 1365-2850
pISSN - 1351-0126
DOI - 10.1111/j.1365-2850.2008.01299.x
Subject(s) - paliperidone , risperidone , schizophrenia (object oriented programming) , paliperidone palmitate , medicine , psychiatry , mood , psychology
Paliperidone prolonged release (PR) is a new product licensed for the treatment of schizophrenia. It is the active metabolite of risperidone, a drug that has been successfully used in the treatment of schizophrenia and mood disorder. Paliperidone PR has a unique pharmacological delivery mechanism that may incur benefits for particular patients diagnosed with schizophrenia. Studies investigating paliperidone PR are reviewed along with implications for its use by nurse prescribers and those nurses who monitor the use of medication for people with psychosis.